Free Trial

Ligand Pharmaceuticals (LGND) SEC Filings & 10K Form

Ligand Pharmaceuticals logo
$121.70 -3.28 (-2.62%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$121.72 +0.02 (+0.02%)
As of 07/11/2025 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Ligand Pharmaceuticals SEC Filings

DateFilerForm TypeView
07/10/2025
4:08 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/03/2025
8:28 AM
Ligand Pharmaceuticals (Reporting)
Pelthos Therapeutics Inc. (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
07/03/2025
8:33 AM
Ligand Pharmaceuticals (Reporting)
Pelthos Therapeutics Inc. (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2025
6:31 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2025
6:32 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2025
6:32 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/02/2025
6:03 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 3/A
07/02/2025
6:10 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/24/2025
7:29 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2025
4:07 PM
Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/12/2025
4:51 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
6:39 PM
Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
6:39 PM
Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
6:20 PM
Haas Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
6:21 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
6:21 PM
Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
6:21 PM
Ligand Pharmaceuticals (Issuer)
Zimmermann Martine (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
6:24 PM
LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
5:49 PM
Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/02/2025
7:05 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/02/2025
7:06 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2025
11:31 AM
JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
05/13/2025
7:04 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2025
7:05 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/08/2025
6:06 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/17/2025
5:08 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/16/2025
8:34 AM
Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2025
5:54 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2025
5:55 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2025
5:55 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/28/2025
3:02 PM
Ligand Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/27/2025
6:06 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/19/2025
7:44 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
7:37 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
7:38 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2025
11:36 AM
JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
12/26/2024
7:32 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2024
7:19 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/06/2024
6:55 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2024
7:05 PM
LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
3:44 PM
LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Trump wipes out trillions overnight… (Ad)

Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.

Whether you take some of that wealth for yourself depends on if you watch this controversial exposé
11/14/2024
2:19 PM
JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G/A
11/08/2024
4:34 PM
GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G/A
11/07/2024
6:11 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/01/2024
3:07 PM
Ligand Pharmaceuticals (Subject)
MACQUARIE GROUP LTD (Filed by)
Form SC 13G/A
09/25/2024
7:54 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2024
6:41 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/24/2024
6:41 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/23/2024
4:27 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/23/2024
4:30 PM
Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/20/2024
5:12 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/20/2024
4:39 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/19/2024
4:50 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2024
6:55 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/30/2024
8:00 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/30/2024
7:56 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/28/2024
3:39 PM
Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/26/2024
7:15 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2024
5:05 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2024
4:21 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/09/2024
4:52 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/09/2024
4:16 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/07/2024
3:30 PM
Ligand Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/17/2024
4:10 PM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:LGND) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners